ResMed Inc. (RMD) has recently exhibited strong performance and growth. The company has seen a boost in sales, particularly in sleep masks and SaaS solutions. Recommendations for the stock are generally positive, with many brokerages giving a consensus of a 'Moderate Buy'. Institutional and investing groups such as Mather Group LLC., GAMMA Investing LLC., and HighPoint Advisor Group LLC are increasing their stake in ResMed. The company's earnings for Q3 surpassed estimates, hinting at a strong financial performance. Furthermore, their new products, specifically the AirCurve 11 device and the AirFit F40 mask, present promising developments in sleep apnea treatment. Negative impact due to potential competition with Eli Lilly’s weight loss drug was short-lived, as the stock rebounded. Insiders like the CEO and CFO have sold some shares, but the company's fundamentals remain strong as demonstrated by a 101% return over the last five years. Yet, there are worries over ResMed's recent share price plunge and investors are encouraged to hold the stock for now. However, stock forecast and price target for 2024 shows a sign of recovery and growth.
Resmed RMD News Analytics from Tue, 26 Sep 2023 07:00:00 GMT to Mon, 24 Jun 2024 01:07:57 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor -3
